Long-Term Clinical Outcome of Tacrolimus Skin Ointment (0.03%) for the Treatment of Vernal Keratoconjunctivitis : A Quasi-Experimental Study
Copyright © 2023, Ali et al..
Background Vernal keratoconjunctivitis (VKC) is an allergic conjunctival inflammation with severe ocular complications if left untreated. The current management regimen is plagued with adverse effects, long-term problems, and clinical relapses. Tacrolimus offers an alternative treatment option, and long-term studies are needed to determine its efficacy. Methods A two-year follow-up based study was conducted on moderate to severe VKC patients, who were prescribed tacrolimus skin ointment. The 5-5-5 exacerbation scale was used for the monitoring and grading severity of the disease. Analysis of variance (ANOVA) and intergroup comparisons were conducted on exacerbation scale scores among follow-ups. Results A significant reduction was observed in the total score of severity from baseline (203.17±102.05) to three months' follow-up (69.94±70.54), and it kept reducing for 18 months post therapy. Similar results with statistically significant reduction were observed for all grades of the scale. The relapse rate was 5.71% within a month after therapy cessation, and none of the other patients showed relapse afterward. No significant ocular and systemic complications were observed during the study. Conclusion Tacrolimus is effective in the long-term management of VKC without the complications of conventional steroid-based therapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Cureus - 15(2023), 12 vom: 12. Dez., Seite e50579 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ali, Warda [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Conjunctivits |
|---|
| Anmerkungen: |
Date Revised 17.01.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.7759/cureus.50579 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367166658 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367166658 | ||
| 003 | DE-627 | ||
| 005 | 20240117232219.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240116s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.7759/cureus.50579 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1262.xml |
| 035 | |a (DE-627)NLM367166658 | ||
| 035 | |a (NLM)38226116 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ali, Warda |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Long-Term Clinical Outcome of Tacrolimus Skin Ointment (0.03%) for the Treatment of Vernal Keratoconjunctivitis |b A Quasi-Experimental Study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 17.01.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2023, Ali et al. | ||
| 520 | |a Background Vernal keratoconjunctivitis (VKC) is an allergic conjunctival inflammation with severe ocular complications if left untreated. The current management regimen is plagued with adverse effects, long-term problems, and clinical relapses. Tacrolimus offers an alternative treatment option, and long-term studies are needed to determine its efficacy. Methods A two-year follow-up based study was conducted on moderate to severe VKC patients, who were prescribed tacrolimus skin ointment. The 5-5-5 exacerbation scale was used for the monitoring and grading severity of the disease. Analysis of variance (ANOVA) and intergroup comparisons were conducted on exacerbation scale scores among follow-ups. Results A significant reduction was observed in the total score of severity from baseline (203.17±102.05) to three months' follow-up (69.94±70.54), and it kept reducing for 18 months post therapy. Similar results with statistically significant reduction were observed for all grades of the scale. The relapse rate was 5.71% within a month after therapy cessation, and none of the other patients showed relapse afterward. No significant ocular and systemic complications were observed during the study. Conclusion Tacrolimus is effective in the long-term management of VKC without the complications of conventional steroid-based therapy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a conjunctivits | |
| 650 | 4 | |a long term | |
| 650 | 4 | |a tacrolimus | |
| 650 | 4 | |a topical steroid | |
| 650 | 4 | |a vernal keratoconjunctivitis | |
| 700 | 1 | |a Alam Khan, Saad |e verfasserin |4 aut | |
| 700 | 1 | |a Ullah Khan, Fahim |e verfasserin |4 aut | |
| 700 | 1 | |a Khan, Shama |e verfasserin |4 aut | |
| 700 | 1 | |a Khan, Wajid A |e verfasserin |4 aut | |
| 700 | 1 | |a Zafar, Rabeeah |e verfasserin |4 aut | |
| 700 | 1 | |a Moqeet, Muhammad A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cureus |d 2013 |g 15(2023), 12 vom: 12. Dez., Seite e50579 |w (DE-627)NLM24118083X |x 2168-8184 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2023 |g number:12 |g day:12 |g month:12 |g pages:e50579 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.7759/cureus.50579 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2023 |e 12 |b 12 |c 12 |h e50579 | ||